Retrophin Reports Third Quarter 2017 Financial Results By Publisher on November 7, 2017 Networking, Picture Gallery Phase 3 FORT Study of fosmetpantotenate continues to enroll PKAN patients Third quarter revenues increased 19 percent to $40 million